Management of Thyroid carcinoma: Hahnemann experience
نویسندگان
چکیده مقاله:
The primary treatment of thyroid carcinoma is surgery and the outcome depends on its extent. The post-operative management alternatives in thyroid carcinoma include thyroid hormone, radio-iodine ablation (I-131 Na), external beam radiation therapy (EBRT) and occasionally adjuvant chemotherapy. This retrospective study analyzes the managements of 153 patients (102, 51), age range 10-96 years, mean age 50.2 years treated for thyroid carcinoma. The range of follow-up was 1.0-294 months with median follow-up for 60.4 months. Twenty patients without therapy were excluded. Group A included 87 patients treated with I-131. Group B consisted of 13 patients received EBRT. Group C included both therapies in 33 patients. The therapies in all different stages of thyroid carcinoma and with various histopathologies were reviewed.
منابع مشابه
management of thyroid carcinoma: hahnemann experience
the primary treatment of thyroid carcinoma is surgery and the outcome depends on its extent. the post-operative management alternatives in thyroid carcinoma include thyroid hormone, radio-iodine ablation (i-131 na), external beam radiation therapy (ebrt) and occasionally adjuvant chemotherapy. this retrospective study analyzes the managements of 153 patients (102, 51), age range 10-96 years, me...
متن کاملA Role for Radiotherapy in the Management of Advanced Medullary Thyroid Carcinoma: the Mayo Clinic Experience
Outcomes of external beam radiotherapy (EBRT) in advanced medullary thyroid carcinoma (MTC) are largely unknown. Retrospective review of data from patients with MTC, diagnosed from June 1, 1970, through December 31, 2007. Overall survival and locoregional tumor control rates were calculated. Seventeen patients had adjuvant or palliative EBRT delivered to 41 sites. Six patients initially had adj...
متن کاملPAPILLARY THYROID CARCINOMA IN MASHHAD
Thyroid cancer is the most common endocrine malignancy. This study surveys the pathologic characteristics of thyroid cancerin Mashhad and study of papillary carcinoma in more detail. In this retrospective study, 108 out of 197 cases of thyroid cancer were papillary in type (55%), with female to male ratio of 1.91 which is lower than current reports. The age at the time of diagnosis ranged ...
متن کاملClinical experience of thyroid carcinoma: a study of 178 cases
AIM OF THE STUDY Thyroid carcinoma is the most common malignancy of endocrine organs. The prognosis varies. Factors such as age, sex, size of the tumor, stage of disease, presence of extrathyroidal spread, and completeness of resection have been found to significantly influence prognosis. We aimed to evaluate clinical features of our patients with thyroid carcinoma, prospectively. MATERIAL AN...
متن کاملSurgical treatment of anaplastic thyroid carcinoma. Our experience.
BACKGROUND In anaplastic thyroid carcinoma (ATC) surgical resection associated to radiotherapy and chemotherapy can ameliorate local disease control with occasional long-term survivals. PATIENTS AND METHODS Resection of the tumor was accomplished in 20 ATC patients, with no macroscopic (13 cases) or minimal residual neck disease infiltrating vital structures (7 cases). Ten of these patients (...
متن کاملHahnemann and placebo.
Samuel Hahnemann (1755-1843) known today as the founder of homoeopathy, was - as far as we know - the first physician who administrated placebos to his patient on a systematic and regular basis. This study is based upon unpublished documents (e.g. patients' letters) in the Archives of the Institute for the History of Medicine of the Robert Bosch Foundation in Stuttgart. It also profited from th...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ذخیره در منابع من قبلا به منابع من ذحیره شده{@ msg_add @}
عنوان ژورنال
دوره 9 شماره 1
صفحات 26- 29
تاریخ انتشار 2001-12-01
با دنبال کردن یک ژورنال هنگامی که شماره جدید این ژورنال منتشر می شود به شما از طریق ایمیل اطلاع داده می شود.
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023